To identify targetable early endocrine escape mechanisms and potential candidates for HER2-directed therapies, we performed an interventional phase II clinical trial to assess molecular changes and tumor responses in early-stage HR+/HER2- BC patients treated with short-term NET, with the primary objective of measuring changes in HER1–4 protein levels with NET. The gene discussed is EGFR; the disease is neoplasm.